+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Obstructive Sleep Apnea (OSA)- Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4661515
  • Drug Pipelines
  • October 2018
  • Region: Global
  • 120 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Jazz Pharmaceuticals
  • RespireRx Pharmaceuticals
  • Teva Pharmaceuticals
  • MORE
‘Obstructive Sleep Apnea (OSA)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of AC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Obstructive Sleep Apnea (OSA) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Obstructive Sleep Apnea (OSA) - Disease Understanding and Treatment Algorithm

The Obstructive Sleep Apnea (OSA) market report gives the thorough understanding of the Obstructive Sleep Apnea by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Obstructive Sleep Apnea in the US, Europe, and Japan.

Obstructive Sleep Apnea Epidemiology

The Obstructive Sleep Apnea (OSA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases by Age Group, Total Adult Prevalent cases, Gender Specific Prevalent Cases, Severity Specific Prevalent Cases and Prevalence of Clinical Manifestations of OSA) scenario of Obstructive Sleep Apnea (OSA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, the total number of adult prevalent population of Obstructive Sleep Apnea (OSA) in 7 MM was found to be 1,381,527, in the year 2016.

Obstructive Sleep Apnea Drug Chapters

This segment of the Obstructive Sleep Apnea report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Current treatment landscape of OSA mainly comprises of options including continuous positive airway pressure (CPAP), oral appliances therapy, surgery, and lifestyle changes such as weight loss or body positioning during sleep. Among all these, CPAP is the gold standard treatment for OSA and occupies the largest market share (devices). Mandibular advancement splints are another treatment modality for OSA which is considered as the second line of treatment for OSA. However CPAP is not the only medical device approved for treatment of OSA. On May 1, 2014, FDA approved the first implanted medical device for the treatment of this disorder.

Provigil Oral and Nuvigil Oral are the only approved marketed drugs for OSA in the US. They both are indicated as an adjunct to standard treatment(s) for the underlying obstruction except in the EU5 where it has been withdrawn following an EMA directive in 2010. Detailed chapter for upcoming therapies like Solriamfetol (also known as JZP-110/SKL-N05) (Jazz Pharmaceuticals), and Dronabinol (RespireRx) have been covered in the report.

Obstructive Sleep Apnea Market Outlook

The Obstructive Sleep Apnea market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Obstructive Sleep Apnea in 7MM was found to be USD 197.46 million in 2016, and is expected to increase from 2016-2027.

Obstructive Sleep Apnea Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Obstructive Sleep Apnea Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Obstructive Sleep Apnea Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Obstructive Sleep Apnea Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Obstructive Sleep Apnea market
  • Organize sales and marketing efforts by identifying the best opportunities for Obstructive Sleep Apnea market
  • To understand the future market competition in the Obstructive Sleep Apnea market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Jazz Pharmaceuticals
  • RespireRx Pharmaceuticals
  • Teva Pharmaceuticals
  • MORE
1. Key Insights

2. Obstructive Sleep Apnea (OSA) Market Overview at a Glance
2.1. Market Share (%) Distribution of OSA in 2016
2.2. Market Share (%) Distribution of OSA in 2027

3. Obstructive Sleep Apnea (OSA): Disease Overview
3.1. Introduction
3.2. Severity Based Classification
3.3. Clinical Manifestations of Obstructive Sleep Apnea
3.4. Etiology
3.5. Risk Factors
3.6. Signs and Symptoms
3.7. Pathogenesis of Obstructive Sleep Apnea
3.8. Diagnosis
3.9. Diagnostic Criteria for OSAS
3.10. Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Prevalence of OSA by Age Group in 7MM
4.4. Total Prevalence of OSA in Adults in 7MM

5. Country Wise-Epidemiology of Obstructive Sleep Apnea
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalence of OSA by Age Group in the United States
5.1.3. Prevalence of OSA in Adults in the US
5.2. EU5 Countries
5.2.1. Germany
5.2.2. Prevalence of OSA by Age Group in Germany
5.2.3. Prevalence of OSA in Adults in Germany
5.3. France
5.3.1. Prevalence of OSA by Age Group in France
5.3.2. Prevalence of OSA in Adults in France
5.4. Italy
5.4.1. Prevalence of OSA by Age Group in Italy
5.4.2. Prevalence of OSA in Adults in Italy
5.5. Spain
5.5.1. Prevalence of OSA by Age Group in Spain
5.5.2. Prevalence of OSA in Adults in Spain
5.6. United Kingdom
5.6.1. Prevalence of OSA by Age Group in the United Kingdom
5.6.2. Prevalence of OSA in Adults in the United Kingdom
5.7. Japan
5.7.1. Prevalence of OSA by Age Group in Japan
5.7.2. Prevalence of OSA in Adults in Japan

6. Current Treatment Practices

7. Unmet Needs

8. Marketed drugs
8.1. Key cross competition- Marketed drugs
8.2. Provigil: Teva Pharmaceuticals
8.2.1. Drug Description
8.2.2. Regulatory Milestones
8.2.3. Safety and Efficacy
8.2.4. Product Profile
8.3. Nuvigil: Teva Pharmaceuticals
8.3.1. Drug Description
8.3.2. Regulatory Milestones
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile

9. Emerging Therapies
9.1. Key cross competition- Emerging Therapies
9.2. Solriamfetol: Jazz Pharmaceuticals
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Product Profile
9.3. Dronabinol: RespireRx Pharmaceuticals
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Advantages and Disadvantages
9.3.6. Product Profile

10. Obstructive Sleep Apnea: 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of Obstructive Sleep Apnea in 7MM
10.3. Therapy Based Market Size of Obstructive Sleep Apnea in 7MM

11. Market Outlook by Country

12. The United States: Market Outlook
12.1. United States Market Size
12.1.1. Total Market size of Obstructive Sleep Apnea
12.1.2. Therapy Based Market Size of OSA in the US

13. EU-5 Countries: Market Outlook
13.1. Germany
13.1.1. Total Market size of Obstructive Sleep Apnea
13.1.2. Therapy Based Market Size of OSA in Germany
13.2. France
13.2.1. Total Market size of Obstructive Sleep Apnea in France
13.2.2. Therapy Based Market Size of OSA in France
13.3. Italy
13.3.1. Total Market size of Obstructive Sleep Apnea in Italy
13.3.2. Therapy Based Market Size of OSA in Italy
13.4. Spain
13.4.1. Total Market size of Obstructive Sleep Apnea in Spain
13.4.2. Therapy Based Market Size of OSA in Spain
13.5. United Kingdom
13.5.1. Total Market size of Obstructive Sleep Apnea in the UK
13.5.2. Therapy Based Market Size of OSA in the United Kingdom
13.6. Japan: Market Outlook
13.6.1. Total Market size of Obstructive Sleep Apnea in Japan
13.6.2. Therapy Based Market Size of OSA in Japan

14. Market Drivers

15. Market Barriers

16. Appendix
16.1. Report Methodology

17. The Publisher's Capabilities

18. Disclaimer

19. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Teva Pharmaceuticals
  • Jazz Pharmaceuticals
  • RespireRx Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll